Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
1.990
+0.110 (5.85%)
At close: Mar 9, 2026, 4:00 PM EDT
1.950
-0.040 (-2.01%)
After-hours: Mar 9, 2026, 7:50 PM EDT
Cardiff Oncology Employees
As of December 31, 2025, Cardiff Oncology had 31 total employees, including 30 full-time and 1 part-time employees. The number of employees decreased by 2 or -6.06% compared to the previous year.
Employees
31
Change (1Y)
-2
Growth (1Y)
-6.06%
Revenue / Employee
$19,129
Profits / Employee
-$1,479,871
Market Cap
136.05M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Sangamo Therapeutics | 183 |
| Adagene | 138 |
| Inovio Pharmaceuticals | 134 |
| Connect Biopharma Holdings | 62 |
| Spero Therapeutics | 32 |
| Black Diamond Therapeutics | 24 |
| Genelux | 24 |
CRDF News
- 11 days ago - Cardiff Oncology to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 13 days ago - Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update - GlobeNewsWire
- 18 days ago - Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 5 weeks ago - Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus - Benzinga
- 5 weeks ago - Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript - Seeking Alpha
- 5 weeks ago - Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC - GlobeNewsWire
- 5 weeks ago - Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development - GlobeNewsWire
- 7 weeks ago - Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured Enthusiasm - Seeking Alpha